MIMEDX GROUP, INC.
About MIMEDX GROUP, INC.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $418.6M
- Net income
- $48.6M
- Total assets
- $342.7M
- Market cap
- $557.1M
- Gross margin
- 82.6%
- Operating margin
- 15.3%
- Net margin
- 11.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $418.6M
- Cost of revenue
- $73.0M
- Gross profit
- $345.6M
- Operating expenses
- $281.7M
- Operating income
- $63.9M
- Income tax
- $17.7M
- Net income
- $48.6M
- EPS (basic)
- $0.33
- EPS (diluted)
- $0.32
Balance sheet
- Total assets
- $342.7M
- Current assets
- $277.5M
- Total liabilities
- $86.1M
- Current liabilities
- $64.3M
- Shareholders’ equity
- $256.5M
Cash flow
- Operating cash flow
- $74.0M
- Investing cash flow
- -$6.9M
- Financing cash flow
- -$5.4M
- Net cash flow
- $61.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $557.1M
- P/E ratio
- 11.6
- EPS (diluted)
- $0.32
- Shares outstanding
- 150.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 22, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $48.6M in FY2025.
- Revenue grew 62% from FY2021 to FY2025.
- Gross margin of 82.6%, net margin 11.6%.
- Trading 54% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 11.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MIMEDX GROUP, INC..
Write a review
News about MIMEDX GROUP, INC.
News & sentiment via Polygon.io
